Clinical Trials Logo

Refractory Pediatric Solid Tumor clinical trials

View clinical trials related to Refractory Pediatric Solid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT05302921 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Start date: February 18, 2022
Phase: Phase 2
Study type: Interventional

The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult patients with relapsed or refractory solid tumors.

NCT ID: NCT03628131 Not yet recruiting - Clinical trials for Relapsed Pediatric Solid Tumor

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Start date: October 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy with Pazopanib in pediatric patients with relapsed/refractory solid tumor

NCT ID: NCT02638428 Recruiting - Clinical trials for Relapsed Pediatric AML

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.